» Articles » PMID: 17484888

Hepatitis B Virus X Protein Induces Hepatic Steatosis Via Transcriptional Activation of SREBP1 and PPARgamma

Overview
Specialty Gastroenterology
Date 2007 May 9
PMID 17484888
Citations 119
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Hepatic steatosis occurs frequently in patients with chronic hepatitis B virus (HBV) or chronic hepatitis C virus (HCV) infection. Recently, several studies suggested that steatosis plays an important role as a cofactor in other liver diseases such as hepatic fibrosis, hepatitis, and liver cancer. In contrast to HCV, however, the molecular mechanism by which HBV mediates hepatic steatosis has not been clearly studied. Here, we show the molecular mechanism by which hepatitis B virus X protein (HBx) induces hepatic steatosis.

Methods: Lipid accumulation and the expression of various lipid metabolic genes were investigated in HBx-transfected Chang liver cells, HepG2-HBx stable cells, and HBx-transgenic mice.

Results: Overexpression of HBx induced hepatic lipid accumulation in HepG2-HBx stable cells and HBx-transgenic mice. It also up-regulated the messenger RNA and protein levels of sterol regulatory element binding protein 1, but not peroxisome proliferator-activated receptor alpha (PPARalpha). Moreover, we also determined that the expression of HBx increases PPARgamma gene expression as well as its transcriptional activity in hepatic cells, mediated by CCAAT enhancer binding protein alpha activation. Finally, we showed that HBx expression is able to up-regulate the gene expressions of various lipogenic and adipogenic enzymes in hepatic cells.

Conclusions: We showed that the increased HBx expression causes lipid accumulation in hepatic cells mediated by sterol regulatory element binding protein 1 and PPARgamma, which could be a putative molecular mechanism mediating the pathophysiology of HBV infection.

Citing Articles

Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC).

Misceo D, Mocciaro G, DAmore S, Vacca M Nutr Metab (Lond). 2024; 21(1):112.

PMID: 39716321 PMC: 11668039. DOI: 10.1186/s12986-024-00871-3.


Emerging role of liver-bone axis in osteoporosis.

Gao H, Peng X, Li N, Gou L, Xu T, Wang Y J Orthop Translat. 2024; 48:217-231.

PMID: 39290849 PMC: 11407911. DOI: 10.1016/j.jot.2024.07.008.


Severe Hepatic Steatosis Is Associated With Low-Level Viremia and Advanced Fibrosis in Patients With Chronic Hepatitis B in North America.

Ko H, Patel N, Haylock-Jacobs S, Doucette K, Ma M, Cooper C Gastro Hep Adv. 2024; 1(1):106-116.

PMID: 39129930 PMC: 11307651. DOI: 10.1016/j.gastha.2021.09.005.


Hepatic macrophage niche: a bridge between HBV-mediated metabolic changes with intrahepatic inflammation.

Wang J, Lu H, Li Q Front Immunol. 2024; 15:1414594.

PMID: 39091506 PMC: 11291371. DOI: 10.3389/fimmu.2024.1414594.


Love-hate relationship between hepatitis B virus and type 2 diabetes: a Mendelian randomization study.

Yu Y, Tong K, Hu G, Yang X, Wu J, Bai S Front Microbiol. 2024; 15:1378311.

PMID: 38646627 PMC: 11026703. DOI: 10.3389/fmicb.2024.1378311.